Outcome of patients older than 80 years with diffuse large<scp>B</scp>‐cell lymphoma (<scp>DLBCL</scp>) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions
Stefania Gobba(Aziende Socio Sanitarie Territoriale dei Sette Laghi), Emanuele Zucca(Università della Svizzera italiana), Felicitas Hitz(Kantonsspital St. Gallen), Annarita Conconi(Ospedale degli Infermi), Stefan Diem(University of St.Gallen), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Anastasios Stathis(Princess Margaret Cancer Centre), Kathrin Aprile von Hohenstaufen(Università della Svizzera italiana), Wiebke Gulden‐Sala(Università della Svizzera italiana), Alden A. Moccia(BC Cancer Agency), Gloria Margiotta‐Casaluci(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Graziella Pinotti(Medica (Italy)), Luciano Cascione(Institute of Oncology Research)
Cited by 13
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718